{"id":84317,"topic":"peptides","source":"Labroots","title":"Improved Patient Outcomes Facilitated by C-Peptide Testing, Enabling Reclassification and Therapeutic Changes for Patients with Diabetes - Labroots","url":"https://www.labroots.com/webinar/improved-patient-outcomes-facilitated-c-peptide-testing-enabling-reclassification-therapeutic-change","url_hash":"4d00da8c46a6b5b5b925f4e5ae892a3ddf1212b2","author":"","summary":"Improved Patient Outcomes Facilitated by C-Peptide Testing, Enabling Reclassification and Therapeutic Changes for Patients with Diabetes Labroots","content":"Accurate classification of diabetes is essential for selecting appropriate treatment and improving patient outcomes, yet distinguishing type 1 diabetes (T1D) from type 2 diabetes (T2D) remains a significant clinical challenge.1\nThis webinar explores the role of C-peptide testing as an objective biomarker of endogenous insulin production and beta-cell function and highlights how C-peptide testing can support diabetes classification, guide treatment decisions, and identify individuals who may not require lifelong insulin therapy. \nThis session presents key findings from an ongoing Cardiff pilot study that evaluated 388 individuals clinically diagnosed with Type 1 Diabetes (T1D) for over three years who were antibody-negative or untested.\nAttendees will learn how incorporating routine C-peptide testing improves diagnostic accuracy, enables personalized diabetes care, and drives institutional cost savings.\nLearning Objectives:\nLabroots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.\nGroup viewing options are available - see our CE credit page for more information.\n1. American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S20-S42. doi:10.2337/dc24-S002.","image_url":"https://images.labroots.com/webinar_profile_image_e91bcc6a08f7235954e699838ccc9a2c7fa0628f_5143.png","lang":"en","published_at":"2026-09-15T20:52:51+00:00","fetched_at":"2026-09-17T05:15:10+00:00","status":"read","starred":0,"extract_state":"ok","summary_auto":"Accurate classification of diabetes is essential for selecting appropriate treatment and improving patient outcomes, yet distinguishing type 1 diabetes (T1D) from type 2 diabetes (T2D) remains a significant clinical challenge.1\nThis webinar explores the role of C-peptide testing as an objective biomarker of endogenous insulin production and beta-cell function and highlights how C-peptide testing can support diabetes classification, guide treatment decisions, and identify individuals who may not require lifelong insulin therapy. This session presents key findings from an ongoing Cardiff pilot study that evaluated 388 individuals clinically diagnosed with Type 1 Diabetes (T1D) for over three years who were antibody-negative or untested.","cluster_id":null,"extract_retries":0,"extract_error":null,"contract_version":"news_item.v1","format_contract_version":"news_item_formats.v1","dedup_url":"https://www.labroots.com/webinar/improved-patient-outcomes-facilitated-c-peptide-testing-enabling-reclassification-therapeutic-change","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 1487 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":1487,"summary_length":744,"usable_text_length":1487,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":1487,"summary_length":744}},"news_item":{"id":84317,"canonical_url":"https://www.labroots.com/webinar/improved-patient-outcomes-facilitated-c-peptide-testing-enabling-reclassification-therapeutic-change","source_url":"https://www.labroots.com/webinar/improved-patient-outcomes-facilitated-c-peptide-testing-enabling-reclassification-therapeutic-change","title":"Improved Patient Outcomes Facilitated by C-Peptide Testing, Enabling Reclassification and Therapeutic Changes for Patients with Diabetes - Labroots","source_name":"Labroots","author":null,"published_at":"2026-09-15T20:52:51+00:00","locale":"en","topic":"peptides","tags":[],"rss_summary":"Improved Patient Outcomes Facilitated by C-Peptide Testing, Enabling Reclassification and Therapeutic Changes for Patients with Diabetes Labroots","full_text":"Accurate classification of diabetes is essential for selecting appropriate treatment and improving patient outcomes, yet distinguishing type 1 diabetes (T1D) from type 2 diabetes (T2D) remains a significant clinical challenge.1\nThis webinar explores the role of C-peptide testing as an objective biomarker of endogenous insulin production and beta-cell function and highlights how C-peptide testing can support diabetes classification, guide treatment decisions, and identify individuals who may not require lifelong insulin therapy. \nThis session presents key findings from an ongoing Cardiff pilot study that evaluated 388 individuals clinically diagnosed with Type 1 Diabetes (T1D) for over three years who were antibody-negative or untested.\nAttendees will learn how incorporating routine C-peptide testing improves diagnostic accuracy, enables personalized diabetes care, and drives institutional cost savings.\nLearning Objectives:\nLabroots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.\nGroup viewing options are available - see our CE credit page for more information.\n1. American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S20-S42. doi:10.2337/dc24-S002.","excerpt":"Accurate classification of diabetes is essential for selecting appropriate treatment and improving patient outcomes, yet distinguishing type 1 diabetes (T1D) from type 2 diabetes (T2D) remains a significant clinical challenge.1\nThis webinar explores the role of C-peptide testing as an objective biomarker of endogenous insulin production and beta-cell function and highlights how C-peptide testing can support diabetes classification, guide treatment decisions, and identify individuals who may not require lifelong insulin therapy. This session presents key findings from an ongoing Cardiff pilot study that evaluated 388 individuals clinically diagnosed with Type 1 Diabetes (T1D) for over three years who were antibody-negative or untested.","extraction":{"state":"ok","confidence":0.9,"error":null,"explanation":"High confidence: full text extraction produced 1487 characters.","diagnostics_url":"/api/diagnose?url=https%3A//www.labroots.com/webinar/improved-patient-outcomes-facilitated-c-peptide-testing-enabling-reclassification-therapeutic-change","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 1487 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":1487,"summary_length":744,"usable_text_length":1487,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":1487,"summary_length":744}}},"display_formats":["compact","card","full","digest_section","json"]},"daily_stack_record":{"title":"Improved Patient Outcomes Facilitated by C-Peptide Testing, Enabling Reclassification and Therapeutic Changes for Patients with Diabetes - Labroots","url":"https://www.labroots.com/webinar/improved-patient-outcomes-facilitated-c-peptide-testing-enabling-reclassification-therapeutic-change","summary":"Accurate classification of diabetes is essential for selecting appropriate treatment and improving patient outcomes, yet distinguishing type 1 diabetes (T1D) from type 2 diabetes (T2D) remains a significant clinical challenge.1\nThis webinar explores the role of C-peptide testing as an objective biomarker of endogenous insulin production and beta-cell function and highlights how C-peptide testing can support diabetes classification, guide treatment decisions, and identify individuals who may not require lifelong insulin therapy. This session presents key findings from an ongoing Cardiff pilot study that evaluated 388 individuals clinically diagnosed with Type 1 Diabetes (T1D) for over three years who were antibody-negative or untested.","source":"Labroots","date":"2026-09-15T20:52:51+00:00","content":"Accurate classification of diabetes is essential for selecting appropriate treatment and improving patient outcomes, yet distinguishing type 1 diabetes (T1D) from type 2 diabetes (T2D) remains a significant clinical challenge.1\nThis webinar explores the role of C-peptide testing as an objective biomarker of endogenous insulin production and beta-cell function and highlights how C-peptide testing can support diabetes classification, guide treatment decisions, and identify individuals who may not require lifelong insulin therapy. \nThis session presents key findings from an ongoing Cardiff pilot study that evaluated 388 individuals clinically diagnosed with Type 1 Diabetes (T1D) for over three years who were antibody-negative or untested.\nAttendees will learn how incorporating routine C-peptide testing improves diagnostic accuracy, enables personalized diabetes care, and drives institutional cost savings.\nLearning Objectives:\nLabroots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.\nGroup viewing options are available - see our CE credit page for more information.\n1. American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S20-S42. doi:10.2337/dc24-S002.","confidence":0.9,"diagnostics_url":"/api/diagnose?url=https%3A//www.labroots.com/webinar/improved-patient-outcomes-facilitated-c-peptide-testing-enabling-reclassification-therapeutic-change","quality_bucket":"high","failure_kind":"none","retryable":false,"quality_reason":"High confidence: full text extraction produced 1487 characters.","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 1487 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":1487,"summary_length":744,"usable_text_length":1487,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":1487,"summary_length":744}},"tags":[]},"fallback_formats":["markdown","json","html"],"actions":{"read":"/item/84317","export_markdown":"/api/items/84317/export?format=markdown","export_json":"/api/items/84317/export?format=json","diagnose":"/api/diagnose?url=https%3A//www.labroots.com/webinar/improved-patient-outcomes-facilitated-c-peptide-testing-enabling-reclassification-therapeutic-change"},"formats":{"full":{"id":84317,"title":"Improved Patient Outcomes Facilitated by C-Peptide Testing, Enabling Reclassification and Therapeutic Changes for Patients with Diabetes - Labroots","url":"https://www.labroots.com/webinar/improved-patient-outcomes-facilitated-c-peptide-testing-enabling-reclassification-therapeutic-change","source":"Labroots","author":null,"published_at":"2026-09-15T20:52:51+00:00","locale":"en","topic":"peptides","tags":[],"excerpt":"Accurate classification of diabetes is essential for selecting appropriate treatment and improving patient outcomes, yet distinguishing type 1 diabetes (T1D) from type 2 diabetes (T2D) remains a significant clinical challenge.1\nThis webinar explores the role of C-peptide testing as an objective biomarker of endogenous insulin production and beta-cell function and highlights how C-peptide testing can support diabetes classification, guide treatment decisions, and identify individuals who may not require lifelong insulin therapy. This session presents key findings from an ongoing Cardiff pilot study that evaluated 388 individuals clinically diagnosed with Type 1 Diabetes (T1D) for over three years who were antibody-negative or untested.","full_text":"Accurate classification of diabetes is essential for selecting appropriate treatment and improving patient outcomes, yet distinguishing type 1 diabetes (T1D) from type 2 diabetes (T2D) remains a significant clinical challenge.1\nThis webinar explores the role of C-peptide testing as an objective biomarker of endogenous insulin production and beta-cell function and highlights how C-peptide testing can support diabetes classification, guide treatment decisions, and identify individuals who may not require lifelong insulin therapy. \nThis session presents key findings from an ongoing Cardiff pilot study that evaluated 388 individuals clinically diagnosed with Type 1 Diabetes (T1D) for over three years who were antibody-negative or untested.\nAttendees will learn how incorporating routine C-peptide testing improves diagnostic accuracy, enables personalized diabetes care, and drives institutional cost savings.\nLearning Objectives:\nLabroots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.\nGroup viewing options are available - see our CE credit page for more information.\n1. American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S20-S42. doi:10.2337/dc24-S002.","reading_time_min":1,"extraction":{"state":"ok","confidence":0.9,"error":null,"explanation":"High confidence: full text extraction produced 1487 characters.","diagnostics_url":"/api/diagnose?url=https%3A//www.labroots.com/webinar/improved-patient-outcomes-facilitated-c-peptide-testing-enabling-reclassification-therapeutic-change","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 1487 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":1487,"summary_length":744,"usable_text_length":1487,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":1487,"summary_length":744}}},"quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 1487 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":1487,"summary_length":744,"usable_text_length":1487,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":1487,"summary_length":744}},"actions":{"read":"/item/84317","export_markdown":"/api/items/84317/export?format=markdown","export_json":"/api/items/84317/export?format=json","diagnose":"/api/diagnose?url=https%3A//www.labroots.com/webinar/improved-patient-outcomes-facilitated-c-peptide-testing-enabling-reclassification-therapeutic-change"}},"digest":{"id":84317,"title":"Improved Patient Outcomes Facilitated by C-Peptide Testing, Enabling Reclassification and Therapeutic Changes for Patients with Diabetes - Labroots","url":"https://www.labroots.com/webinar/improved-patient-outcomes-facilitated-c-peptide-testing-enabling-reclassification-therapeutic-change","source":"Labroots","topic":"peptides","published_at":"2026-09-15T20:52:51+00:00","excerpt":"Accurate classification of diabetes is essential for selecting appropriate treatment and improving patient outcomes, yet distinguishing type 1 diabetes (T1D) from type 2 diabetes (T2D) remains a significant clinical challenge.1 This webinar explores the role of C-peptide testing…","quality_bucket":"high","quality_reason":"High confidence: full text extraction produced 1487 characters.","reading_time_min":1,"cluster_id":null},"card":{"display_title":"Improved Patient Outcomes Facilitated by C-Peptide Testing, Enabling Reclassification and Therapeutic Changes for Patients with Diabetes - Labroots","subtitle":"Labroots · 2026-09-15","summary":"Accurate classification of diabetes is essential for selecting appropriate treatment and improving patient outcomes, yet distinguishing type 1 diabetes (T1D) from type 2 diabetes (T2D) remains a significant clinical…","badges":["quality:high"],"links":{"read":"/item/84317","original":"https://www.labroots.com/webinar/improved-patient-outcomes-facilitated-c-peptide-testing-enabling-reclassification-therapeutic-change","diagnose":"/api/diagnose?url=https%3A//www.labroots.com/webinar/improved-patient-outcomes-facilitated-c-peptide-testing-enabling-reclassification-therapeutic-change"},"quality_warning":null},"export":{"title":"Improved Patient Outcomes Facilitated by C-Peptide Testing, Enabling Reclassification and Therapeutic Changes for Patients with Diabetes - Labroots","url":"https://www.labroots.com/webinar/improved-patient-outcomes-facilitated-c-peptide-testing-enabling-reclassification-therapeutic-change","summary":"Accurate classification of diabetes is essential for selecting appropriate treatment and improving patient outcomes, yet distinguishing type 1 diabetes (T1D) from type 2 diabetes (T2D) remains a significant clinical challenge.1\nThis webinar explores the role of C-peptide testing as an objective biomarker of endogenous insulin production and beta-cell function and highlights how C-peptide testing can support diabetes classification, guide treatment decisions, and identify individuals who may not require lifelong insulin therapy. This session presents key findings from an ongoing Cardiff pilot study that evaluated 388 individuals clinically diagnosed with Type 1 Diabetes (T1D) for over three years who were antibody-negative or untested.","source":"Labroots","date":"2026-09-15T20:52:51+00:00","content":"Accurate classification of diabetes is essential for selecting appropriate treatment and improving patient outcomes, yet distinguishing type 1 diabetes (T1D) from type 2 diabetes (T2D) remains a significant clinical challenge.1\nThis webinar explores the role of C-peptide testing as an objective biomarker of endogenous insulin production and beta-cell function and highlights how C-peptide testing can support diabetes classification, guide treatment decisions, and identify individuals who may not require lifelong insulin therapy. \nThis session presents key findings from an ongoing Cardiff pilot study that evaluated 388 individuals clinically diagnosed with Type 1 Diabetes (T1D) for over three years who were antibody-negative or untested.\nAttendees will learn how incorporating routine C-peptide testing improves diagnostic accuracy, enables personalized diabetes care, and drives institutional cost savings.\nLearning Objectives:\nLabroots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.\nGroup viewing options are available - see our CE credit page for more information.\n1. American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S20-S42. doi:10.2337/dc24-S002.","confidence":0.9,"diagnostics_url":"/api/diagnose?url=https%3A//www.labroots.com/webinar/improved-patient-outcomes-facilitated-c-peptide-testing-enabling-reclassification-therapeutic-change","quality_bucket":"high","failure_kind":"none","retryable":false,"quality_reason":"High confidence: full text extraction produced 1487 characters.","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 1487 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":1487,"summary_length":744,"usable_text_length":1487,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":1487,"summary_length":744}},"tags":[],"format_contract_version":"news_item_formats.v1"}}}